Biogen and UCB Release New Data on Lupus Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 57 minutes ago
0mins
Source: NASDAQ.COM
- Clinical Data Release: Biogen and UCB presented clinical data from the PHOENYCS GO program at the EULAR 2026 congress, showcasing the potential of dapirolizumab pegol in treating systemic lupus erythematosus, marking a significant advancement in the biopharmaceutical field.
- Efficacy Assessment: Post-hoc analyses indicated that patients receiving dapirolizumab pegol demonstrated durable disease control by week 48 while tapering glucocorticoid use, highlighting the drug's effectiveness in improving patient quality of life.
- Immunological Marker Changes: Results showed significant reductions in anti-dsDNA antibodies and increases in complement proteins C3 and C4, indicating dapirolizumab pegol's positive role in modulating immune responses, potentially offering new directions for future treatment regimens.
- Market Reaction: Biogen's stock closed up 3.78% on Wednesday, although it fell 2.66% in pre-market trading, reflecting the market's initial response to the new data, while investors will need to monitor the impact of subsequent clinical trial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 188.830
Low
143.00
Averages
204.45
High
246.00
Current: 188.830
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dapirolizumab Pegol Reduces Steroid Use in SLE Patients
- Clinical Trial Results: In the Phase 3 PHOENYCS GO study, patients with systemic lupus erythematosus (SLE) receiving dapirolizumab pegol (DZP) achieved sustained disease control at lower glucocorticoid doses through Week 48, indicating DZP's potential to reduce long-term steroid exposure.
- Immunological Marker Improvements: At the EULAR 2026 Congress, significant reductions in anti-dsDNA antibodies and increases in complement proteins C3 and C4 were observed in the DZP treatment group, demonstrating its effectiveness in improving immune function in SLE patients and potentially reducing flare rates.
- Disease Activity Control: The study revealed that among patients with baseline glucocorticoid doses exceeding 7.5 mg/day, a higher proportion in the DZP group achieved disease activity control through Week 48 compared to the placebo group, emphasizing DZP's ability to maintain disease control while tapering steroids.
- Clinical Significance: The findings from UCB and Biogen highlight that DZP not only reduces steroid use but also improves patient quality of life, aligning with clinicians' needs for long-term management of SLE, thus holding significant strategic importance.
See More
Biogen Showcases Nephrology Portfolio at Major Medical Congresses
- Nephrology Research Highlights: Biogen presented 14 abstracts at the 63rd European Renal Association Congress and the 2026 American Transplant Congress, showcasing its nephrology portfolio including EMPAVELI® (pegcetacoplan) and investigational felzartamab, demonstrating the company's extensive influence in the kidney disease sector.
- Clinical Trial Insights: New post-hoc analyses from the VALIANT and VALE studies presented at ERA indicate that EMPAVELI maintains efficacy and safety over one year in patients with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, reinforcing its market position.
- Therapeutic Innovations: At ATC, analyses of the Phase 2 felzartamab trial reveal significant impacts on antibody-mediated rejection in patients with a long history of rejection, potentially offering new solutions for treating late-stage AMR and improving patient outcomes.
- Strategic Partnerships: Biogen's collaboration with Sobi secures commercial rights for EMPAVELI outside the U.S., highlighting the company's strategic positioning globally to enhance patient quality of life through innovative therapies and drive long-term growth.
See More
Biogen Receives FDA Breakthrough Therapy Designation for Salanersen
- FDA Breakthrough Therapy Designation: Biogen announced that its investigational drug salanersen has received Breakthrough Therapy Designation from the FDA for the treatment of spinal muscular atrophy (SMA), a designation aimed at expediting the development and review of drugs intended for serious conditions, indicating the FDA's recognition of the drug's potential for significant clinical improvement.
- Positive Clinical Trial Results: In the Phase 1b study, salanersen demonstrated slowing of neurodegeneration and clinically meaningful improvements in motor function in children previously treated with gene therapy, with 12 out of 24 participants achieving new motor milestones, highlighting the drug's potential to enhance patient quality of life.
- Global Research Program Initiation: The Phase 3 program for salanersen includes three global studies: STELLAR-1, STELLAR-2, and SOLAR, designed to evaluate the drug's safety and efficacy across various age groups and treatment backgrounds, potentially providing new solutions for SMA treatment.
- Broad Market Potential: The development of salanersen reflects Biogen's ongoing commitment to the SMA field and addresses unmet medical needs, which may lay the groundwork for future growth and increased market share for the company.
See More
Biogen and UCB Release New Data on Lupus Treatment
- Clinical Data Release: Biogen and UCB presented clinical data from the PHOENYCS GO program at the EULAR 2026 congress, showcasing the potential of dapirolizumab pegol in treating systemic lupus erythematosus, marking a significant advancement in the biopharmaceutical field.
- Efficacy Assessment: Post-hoc analyses indicated that patients receiving dapirolizumab pegol demonstrated durable disease control by week 48 while tapering glucocorticoid use, highlighting the drug's effectiveness in improving patient quality of life.
- Immunological Marker Changes: Results showed significant reductions in anti-dsDNA antibodies and increases in complement proteins C3 and C4, indicating dapirolizumab pegol's positive role in modulating immune responses, potentially offering new directions for future treatment regimens.
- Market Reaction: Biogen's stock closed up 3.78% on Wednesday, although it fell 2.66% in pre-market trading, reflecting the market's initial response to the new data, while investors will need to monitor the impact of subsequent clinical trial results.
See More
UCB and Biogen's Drug Trial Achieves Success
- Clinical Trial Results: UCB and Biogen's dapirolizumab pegol met its primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011), indicating significant clinical benefit of the drug.
- Treatment Effectiveness Assessment: BICLA serves as a composite endpoint measuring clinically relevant improvement across all affected organ systems without worsening in other lupus domains, reflecting the efficacy of dapirolizumab pegol in treatment, despite the first key secondary endpoint not being met.
- Adverse Event Rates: The serious adverse event rate for dapirolizumab pegol was 10%, lower than the 14.8% observed in the placebo group, suggesting a relatively higher safety profile for the drug, which may enhance patient confidence in treatment.
- Future Research Plans: The confirmatory phase 3 PHOENYCS FLY trial is currently recruiting patients, aiming to further validate the efficacy and safety of dapirolizumab pegol, laying the groundwork for future market introduction.
See More
Dapirolizumab Pegol Shows Significant Clinical Trial Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving Dapirolizumab Pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Improvement Across Multiple Metrics: The study demonstrated that Dapirolizumab Pegol showed advantages across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patients' quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the Dapirolizumab Pegol group successfully reduced their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of Dapirolizumab Pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, but serious adverse events were lower at 10.0%, indicating its feasibility for clinical use.
See More
Dapirolizumab Pegol Reduces Steroid Use in SLE Patients
- Clinical Trial Results: In the Phase 3 PHOENYCS GO study, patients with systemic lupus erythematosus (SLE) receiving dapirolizumab pegol (DZP) achieved sustained disease control at lower glucocorticoid doses through Week 48, indicating DZP's potential to reduce long-term steroid exposure.
- Immunological Marker Improvements: At the EULAR 2026 Congress, significant reductions in anti-dsDNA antibodies and increases in complement proteins C3 and C4 were observed in the DZP treatment group, demonstrating its effectiveness in improving immune function in SLE patients and potentially reducing flare rates.
- Disease Activity Control: The study revealed that among patients with baseline glucocorticoid doses exceeding 7.5 mg/day, a higher proportion in the DZP group achieved disease activity control through Week 48 compared to the placebo group, emphasizing DZP's ability to maintain disease control while tapering steroids.
- Clinical Significance: The findings from UCB and Biogen highlight that DZP not only reduces steroid use but also improves patient quality of life, aligning with clinicians' needs for long-term management of SLE, thus holding significant strategic importance.
See More
Biogen Showcases Nephrology Portfolio at Major Medical Congresses
- Nephrology Research Highlights: Biogen presented 14 abstracts at the 63rd European Renal Association Congress and the 2026 American Transplant Congress, showcasing its nephrology portfolio including EMPAVELI® (pegcetacoplan) and investigational felzartamab, demonstrating the company's extensive influence in the kidney disease sector.
- Clinical Trial Insights: New post-hoc analyses from the VALIANT and VALE studies presented at ERA indicate that EMPAVELI maintains efficacy and safety over one year in patients with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, reinforcing its market position.
- Therapeutic Innovations: At ATC, analyses of the Phase 2 felzartamab trial reveal significant impacts on antibody-mediated rejection in patients with a long history of rejection, potentially offering new solutions for treating late-stage AMR and improving patient outcomes.
- Strategic Partnerships: Biogen's collaboration with Sobi secures commercial rights for EMPAVELI outside the U.S., highlighting the company's strategic positioning globally to enhance patient quality of life through innovative therapies and drive long-term growth.
See More
Biogen Receives FDA Breakthrough Therapy Designation for Salanersen
- FDA Breakthrough Therapy Designation: Biogen announced that its investigational drug salanersen has received Breakthrough Therapy Designation from the FDA for the treatment of spinal muscular atrophy (SMA), a designation aimed at expediting the development and review of drugs intended for serious conditions, indicating the FDA's recognition of the drug's potential for significant clinical improvement.
- Positive Clinical Trial Results: In the Phase 1b study, salanersen demonstrated slowing of neurodegeneration and clinically meaningful improvements in motor function in children previously treated with gene therapy, with 12 out of 24 participants achieving new motor milestones, highlighting the drug's potential to enhance patient quality of life.
- Global Research Program Initiation: The Phase 3 program for salanersen includes three global studies: STELLAR-1, STELLAR-2, and SOLAR, designed to evaluate the drug's safety and efficacy across various age groups and treatment backgrounds, potentially providing new solutions for SMA treatment.
- Broad Market Potential: The development of salanersen reflects Biogen's ongoing commitment to the SMA field and addresses unmet medical needs, which may lay the groundwork for future growth and increased market share for the company.
See More
Biogen and UCB Release New Data on Lupus Treatment
- Clinical Data Release: Biogen and UCB presented clinical data from the PHOENYCS GO program at the EULAR 2026 congress, showcasing the potential of dapirolizumab pegol in treating systemic lupus erythematosus, marking a significant advancement in the biopharmaceutical field.
- Efficacy Assessment: Post-hoc analyses indicated that patients receiving dapirolizumab pegol demonstrated durable disease control by week 48 while tapering glucocorticoid use, highlighting the drug's effectiveness in improving patient quality of life.
- Immunological Marker Changes: Results showed significant reductions in anti-dsDNA antibodies and increases in complement proteins C3 and C4, indicating dapirolizumab pegol's positive role in modulating immune responses, potentially offering new directions for future treatment regimens.
- Market Reaction: Biogen's stock closed up 3.78% on Wednesday, although it fell 2.66% in pre-market trading, reflecting the market's initial response to the new data, while investors will need to monitor the impact of subsequent clinical trial results.
See More
UCB and Biogen's Drug Trial Achieves Success
- Clinical Trial Results: UCB and Biogen's dapirolizumab pegol met its primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011), indicating significant clinical benefit of the drug.
- Treatment Effectiveness Assessment: BICLA serves as a composite endpoint measuring clinically relevant improvement across all affected organ systems without worsening in other lupus domains, reflecting the efficacy of dapirolizumab pegol in treatment, despite the first key secondary endpoint not being met.
- Adverse Event Rates: The serious adverse event rate for dapirolizumab pegol was 10%, lower than the 14.8% observed in the placebo group, suggesting a relatively higher safety profile for the drug, which may enhance patient confidence in treatment.
- Future Research Plans: The confirmatory phase 3 PHOENYCS FLY trial is currently recruiting patients, aiming to further validate the efficacy and safety of dapirolizumab pegol, laying the groundwork for future market introduction.
See More
Dapirolizumab Pegol Shows Significant Clinical Trial Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving Dapirolizumab Pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Improvement Across Multiple Metrics: The study demonstrated that Dapirolizumab Pegol showed advantages across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patients' quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the Dapirolizumab Pegol group successfully reduced their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of Dapirolizumab Pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, but serious adverse events were lower at 10.0%, indicating its feasibility for clinical use.
See More
